| Ytd | -7.95% | |
| 1y | -28.57% |
| Open | 2.24 | Prev Close | 2.24 | Low | 2.19 | High | 2.25 | Mkt Cap | 68.29M |
| Vol | 38.84K | Avg Vol | 31.84K | EPS | -1.32 | P/E | -1.70 | Forward P/E | 34.62 |
| Beta | 0.86 | Short Ratio | 15.03 | Inst. Own | 16.19% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | 07-15 | Earning | 08-15 | 50-d Avg | 2.37 | 200-d Avg | 2.42 | 1yr Est | 13.00 |
XBIT News
XBiotech Inc. (NASDAQ:XBIT) today announced that its Investigational New Drug (IND) application for
IND Application for V-SPINE Study Completes 30-Day FDA Review Without Clinical Hold, Clearing Path f
XBiotech (NASDAQ:XBIT) reported quarterly losses of $(0.18) per share. This is a 50 percent increase
IN8bio (NASDAQ: INAB - Get Free Report) and XBiotech (NASDAQ: XBIT - Get Free Report) are both small
Psyence Biomedical (NASDAQ: PBM - Get Free Report) and XBiotech (NASDAQ: XBIT - Get Free Report) are
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers;
XBiotech Inc. (NASDAQ: XBIT - Get Free Report) passed above its 50 day moving average during trading
XBiotech (NASDAQ:XBIT) reported quarterly losses of $(0.20) per share. This is a 25 percent decrease
XBiotech (NASDAQ:XBIT) reported quarterly losses of $(0.06) per share. This is a 86.05 percent incre
LOS ANGELES, CA / ACCESS Newswire / March 2, 2025 / The Schall Law Firm, a national shareholder righ
LOS ANGELES, CA / ACCESS Newswire / March 1, 2025 / The Schall Law Firm, a national shareholder righ
LOS ANGELES, CA / ACCESS Newswire / February 28, 2025 / The Schall Law Firm, a national shareholder
LOS ANGELES, CA / ACCESS Newswire / February 27, 2025 / The Schall Law Firm, a national shareholder
LOS ANGELES, CA / ACCESS Newswire / February 26, 2025 / The Schall Law Firm, a national shareholder
LOS ANGELES, CA / ACCESS Newswire / February 25, 2025 / The Schall Law Firm, a national shareholder
LOS ANGELES, CA / ACCESS Newswire / February 24, 2025 / The Schall Law Firm, a national shareholder
LOS ANGELES, CA / ACCESS Newswire / February 23, 2025 / The Schall Law Firm, a national shareholder
LOS ANGELES, CA / ACCESS Newswire / February 22, 2025 / The Schall Law Firm, a national shareholder
LOS ANGELES, CA / ACCESS Newswire / February 21, 2025 / The Schall Law Firm, a national shareholder
LOS ANGELES, CA / ACCESS Newswire / February 20, 2025 / The Schall Law Firm, a national shareholder
LOS ANGELES, CA / ACCESS Newswire / February 19, 2025 / The Schall Law Firm, a national shareholder
LOS ANGELES, CA / ACCESS Newswire / February 18, 2025 / The Schall Law Firm, a national shareholder
LOS ANGELES, CA / ACCESS Newswire / February 17, 2025 / The Schall Law Firm, a national shareholder
LOS ANGELES, CA / ACCESS Newswire / February 16, 2025 / The Schall Law Firm, a national shareholder
LOS ANGELES, CA / ACCESS Newswire / February 15, 2025 / The Schall Law Firm, a national shareholder
XBiotech reveals results from its Phase 1/Phase 2 1-BETTER Study for advanced pancreatic cancer, hig
XBiotech (NASDAQ:XBIT) announced today data from its Phase 1/Phase 2 randomized, double-blind, place
On Monday, 79 companies reached new 52-week lows.
On Thursday, 1076 companies hit new 52-week lows.
On Monday, 721 companies achieved new lows for the year.
During Thursday, 166 stocks hit new 52-week lows.